Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
Zacks
New At-Home Surity Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence
New At-Home Surity Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence New At-Home Surity Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence PR Newswire MLNDAL, Sweden...
PR Newswire
HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates
Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.
Zacks
How the U.K. VAT Ruling Could Reshape Align's 2026 Earnings Outlook
Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.
Zacks
Should Investors Buy Align as Growth Meets Valuation and Demand Risks?
ALGN's record Clear Aligner growth and global adoption support the bull case, but demand softness and scanner pricing pressure keep investors cautious.
Zacks
Can NVST Sustain Its 2026 Guidance Boost as Margins Keep Expanding?
Envista raises 2026 guidance as stronger sales and expanding margins lift earnings, but China pricing, tariffs and a tougher Q4 loom.
Zacks
Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Is NVST a Buy as Earnings Rebound but Valuation Remains Above Median?
Envista's earnings rebound and raised 2026 guidance strengthen the case, but above-median valuation leaves less room for execution setbacks.
Zacks
XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.
Zacks
Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 Earnings
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks